CGL
JUNO

Clarius Group LLC’s Juno Therapeutics, Inc. JUNO Stock Holding History

Clarius Group LLC’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-120,988
Closed -$5.53M – 69
2017
Q4 		$5.53M Buy
120,988
+3,092
+3% +$154K 2.47% 6
2017
Q3 		$5.29M Sell
117,896
-128
-0.1% -$4.36K 2.23% 8
2017
Q2 		$3.53M Buy
118,024
+128
+0.1% +$3.16K 1.45% 13
2017
Q1 		$2.62M Hold
117,896
– – 1.08% 13
2016
Q4 		$2.22M Hold
117,896
– – 0.94% 18
2016
Q3 		$3.54M Buy
117,896
+3,500
+3% +$109K 1.65% 12
2016
Q2 		$4.94M Hold
114,396
– – 2.63% 4
2016
Q1 		$4.36M Buy
114,396
+4,925
+4% +$172K 2.42% 5
2015
Q4 		$4.81M Buy
+109,471
New +$5.43M 2.79% 5

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Clarius Group LLC's JUNO Position: Q1 2018 in Review

Clarius Group LLC sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 120,988 shares — an estimated $5.53M sold.

Clarius Group LLC first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $5.53M in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Clarius Group LLC reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Clarius Group LLC sold 120,988 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $5.53M.
  • Clarius Group LLC first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
  • Clarius Group LLC's Juno Therapeutics, Inc. position peaked at $5.53M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Clarius Group LLC's 13F filing for Q1 2018, filed 14 May 2018.